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training and workload is carefully considered to mitigate risks 
to patients.  
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Purpose or Objective: During the course of head and neck 
radiotherapy, anatomical changes may lead to underdosage 
or hotspots in target volumes, and overdosage in organs at 
risk (OARs). The largest dose differences between planned 
and actual given OAR dose have been reported for the 
parotid glands (PGs). Dose increase to the PGs could lead to 
an increase of radiation induced side effects, justifying 
adaptive radiotherapy (ART) to reduce the PG dose. Still, ART 
procedures are labour intensive and only a fraction of 
patients will benefit. The aim of this study was to develop 
and validate a method to predict dose deviations from the 
planned PG mean dose, to select patients for adaptive 
radiotherapy (ART) up-front. 
 
Material and Methods: Planning and response (6 weeks after 
RT) CT-scans from 113 head and neck cancer patients (cohort 
A) were used to estimate deviations between planned and 
actually given PG mean dose (ΔDmean). Potential pre-
treatment selection parameters presented in recent 
literature were included in the analysis. Uni- and 
multivariable linear regression analysis for the endpoint PG 
ΔDmean was performed to select pre-treatment parameters 
eligible for patient selection. ROC curve analysis was 
performed to determine cut off values for selecting patients 
with PG ΔDmean larger than 3 Gy with a sensitivity in the 
range of 70-100%. The proposed method of patient selection 
was validated in another patient cohort consisting of 43 head 
and neck cancer patients who received weekly rescan CTs 
(cohort B). 
 
Results: In univariable analysis, pre-treatment parameters 
significantly associated with PG ΔDmean were: BMI, 
chemotherapy, T-stage, N-stage, volume of the GTV, tumour 
location, overlap of the PG with the high and low dose PTV, 
V20, V30, V40 and mean dose of the PG. In multivariable 
analysis, the initial PG mean dose remained the only 
significant parameter. ROC results were summarized in Table 
1. Selection of patients for dose deviations larger than 3 Gy 
with a sensitivity of 90% could be obtained by a threshold of 
the initial PG mean dose of 22.2 Gy (Table 1). This would 
select 62% of patients for ART in cohort A and 76% in cohort B 
with a corresponding precision of 29 and 19%, saving 38 and 
24% of patients from the labour-intensive ART procedure. 
 
Conclusion: We succeeded to develop a method to select 
patients for ART up-front by using the initial mean dose to 
the parotid gland. The labour of ART could be reduced by 24-
38% with 87-90% sensitivity, contributing to a more effective 
allocation of the department resources. 
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Background: Breast cancer radiotherapy reduces the risk of 
cancer recurrence and death. However it usually involves 
some radiation exposure of the heart which may increase the 
risk of subsequent heart disease. Epidemiological data 
suggest that the major coronary event rate increases by 7.4% 
per Gy mean heart dose1. Estimates of the absolute risks of 
radiation-related heart disease are needed to help 
oncologists plan each individual woman’s treatment. The 
absolute risk for an individual woman depends on her 
estimated cardiac radiation dose and her background risk of 
ischaemic heart disease in the absence of radiotherapy. 
When the risk is known, it can then be compared with the 
absolute benefit of the radiotherapy.  
 
Methods: Worldwide data on heart doses in breast cancer 
radiotherapy published during 2003-2013 were collated 
systematically. Analyses considered the variation in the 
typical mean heart dose according to various patient and 
treatment-related factors including laterality, target(s) 
irradiated and technique2. These heart doses were used to 
predict typical absolute cardiac risks from breast cancer 
radiotherapy using the dose-response relationship of a 7.4% 
per Gy increase in the rate of major coronary events.1 These 
risks were compared with estimates of the absolute benefits 
of breast cancer radiotherapy.  
 
Results: In left breast cancer, mean heart dose averaged 
over 398 regimens in 149 studies from 28 countries was 5.4 
Gy (range <0.1-28.6 Gy). In left-sided regimens that did not 
include the internal mammary chain, the average mean heart 
dose was 5.6 Gy (range <0.1-23.0) for inverse-planned 
intensity modulated radiation therapy, 3.4 Gy (range <0.1-
12.4) for tangential irradiation, 2.2 Gy (range <0.1-3.8) for 
brachytherapy and 0.5 Gy (range 0.1-0.8) for proton beam 
therapy. On average, inclusion of the left IMC doubled the 
heart dose. In 93 regimens where the left IMC was irradiated, 
average mean heart dose was around 8 Gy for most photon or 
electron techniques, and it varied little according to which 
other targets were irradiated. In right-sided breast cancer, 
the average mean heart dose was 3.3 Gy based on 45 
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regimens in 23 studies.2 Applying these doses to estimated 
typical absolute cardiac risks1 showed the absolute risk of a 
radiation-induced major coronary event for many women 
today is less than 1%. So for them, the risk of radiotherapy is 
likely to be much smaller than the benefit. Nevertheless 
there is considerable variation in predicted absolute cardiac 
risks, depending on an individual woman’s background risk 
and on her heart radiation dose.  
 
Conclusions: Exposure of the heart from breast cancer 
radiotherapy has reduced substantially over the past few 
decades but there is still considerable variation in published 
heart doses worldwide. In addition, there is variation in the 
risk of heart disease among patients being considered for 
radiotherapy. Thus there is likely to be substantial 
interpatient variability in the cardiac risks of radiotherapy. 
The population-based dose-response relationship1 can be 
used to provide reassurance for many women that their 
absolute risk of ischaemic heart disease from breast cancer 
radiotherapy is likely to be small compared with their likely 
absolute benefit. For other women, for example those with a 
high predicted heart radiation dose or for those with prior 
heart disease, the dose-response relationship can be used to 
identify the minority of women for whom the risk-benefit 
ratio is less favourable. In these women, consideration may 
be given to reducing cardiac radiation dose to reduce the 
radiation-related cardiac risk.  
Funding This work was funded by core funding from Cancer 
Research UK to the CTSU, University of Oxford and the 
Department of Health, London (project grant RRX 108).  
Conflicts of interest None  
 
References 
1. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic 
heart disease in women after radiotherapy for breast cancer. 
NEJM 2013; 368: 987-998. 
2. Taylor CW, Wang Z, Macaulay E, et al. Exposure of the 
heart in breast cancer radiation therapy: A systematic review 
of heart doses published during 2003-2013. Int J Radiat Oncol 
Biol Phys 2015; 93: 845-853. 
 
SP-0397  
Predicting cardiac toxicity after breast irradiation: new 
quantitative data and new challenges 
G. Gagliardi
1Karolinska University Hospital, Section of Radiotherapy 
Physics and Engineering- Dept of Medical Physics, Stockholm, 
Sweden 
1 
 
The QUANTEC summary of data on dose-volume-response 
effect in heart after radiation therapy provided some answers 
and practical guidelines for the optimization of the dose 
distribution in breast cancer patients, and left a few 
problems open. The main dilemma centered on the fact that 
cardiac serious events are late, requiring long follow-up and 
rare, requiring large populations. Furthermore, in studies 
evaluating cardiac toxicities after irradiation the quality of 
the outcome clinical data was in general different from the 
quality of the dosimetrical data. Similar considerations still 
apply to a few studies performed after QUANTEC.  
A main step forward is represented by the increased size and 
design of the studies, e.g. as in the one by Darby et al (N 
Engl J Med 2013) which included about 2.000 women treated 
in Scandinavia. The paper provided among several results an 
estimation of the cumulative risk of death from ischemic 
heart disease for patients treated/not treated with radiation 
therapy and with different mean heart doses, obtained 
through reconstruction of the dose planning on a model 
patient.  
Beyond size and type of study population another relevant 
factor investigated in several analysis is the relationship 
between fraction size and late cardiac effects. Mahrin ( Int J 
Radiation Oncology Biol. Phys. 2007) performed an analysis 
on about 3.800 left sided respectively 3700 right sided breast 
cancer patients treated between 1984 and 2000, compared 
the different fractionation schedules and concluded that a 
statistical increase in overall and cardiac-specific mortality 
could not be found comparing left vs right breast cancer 
patients. Furthermore the hypofractionated adjuvant RT 
regimens did not significantly increase the risk of cardiac 
mortality. The 10 year follow-up of the START - UK 
Standardization of Breast Cancer Radiotherapy trials of 
radiotherapy hypofractionation (Haviland JS et al, Lancet 
Oncol 2013) confirmed the 5 years results that “appropriately 
dosed hypofractionated radiotherapy is safe and effective”. A 
norwegian study with a longer follow-up, but a smaller study 
population and irradiated in a different way concluded 
instead than the degree of hypofractionation and parasternal 
nodes contributed to an increased cardiac mortality in the 
patient cohort (Tjessem et al, Int J Radiation Oncology Biol. 
Phys 2013).  
Another perspective is given by the studies on cardiac dose-
volume effects where dose distributions in subregions of the 
heart are investigated (e.g. Nilsson G et al, J Clin Oncol 
2012; Johansen S, Breast cancer: basic and clinical research 
2013). The results from these analyis might be very helpful in 
the design of treatment protocols.  
Finally the technological development has to be taken into 
account (e.g. gating, DIBH etc), which in some cases might 
simply by-pass the issue of cardiac irradiation. This approach 
does not provide answers to the basic question, but provides 
a convenient solution.  
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Hodgkin lymphoma is a relatively rare form of cancer, which 
mainly effects young adolescents and young adults. Over the 
past decades developments in treatment options for patients 
with Hodgkin lymphoma have led to improved outcome rates. 
As a result, there is an increasing number of Hodgkin 
lymphoma survivors. They are at risk of developing long-term 
toxicity due to treatment such as secondary malignancies or 
cardiovascular complications. There is an increased risk of 
developing valvular heart disease after mediastinal 
radiotherapy, although risk increases significantly after 
radiation treatment doses over 30 Gy (1). Recent studies also 
show a 4-6 fold increased standardized incidence ratio of 
heart failure and coronary heart disease (CHD), due to 
anthracycline containing chemotherapy regimens and 
mediastinal radiotherapy (2). Severe CHD can even be 
present in the absence of typical symptoms such as chest 
pain (3). A linear dose-response relationship between 
mediastinal radiotherapy and CHD has been established with 
a 2.5-fold increased risk of CHD after receiving a mean heart 
dose of 20 Gy (4). This implies that even patients treated 
with current standard radiotherapy doses remain at serious 
risk of developing radiation induced CHD. At the same time, 
new strategies for non-invasive screening for CHD have 
developed, by means of CT coronary angiography, showing 
encouraging positive and negative predictive values for 
detecting significant CHD. In this lecture, an overview of 
recent efforts of screening for coronary artery disease in 
Hodgkin lymphoma patients is presented, and clinical 
implications are discussed. 
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